Indivior recently released results from a multicenter, open-label clinical trial showing that rapid induction with SUBLOCADE, using a single 4 mg oral buprenorphine dose followed by a same-day ...

If you’re considering treatment for opioid use disorder (OUD), your doctor may recommend Sublocade. It’s prescribed as part of a complete treatment program to manage opioid addiction in adults with ...

Indivior (NasdaqGS:INDV) just released new clinical trial data showing that rapid induction with its opioid use disorder treatment, SUBLOCADE, is linked with higher patient retention compared to ...

Sublocade (buprenorphine) is a brand-name subcutaneous injection prescribed for opioid use disorder. It works to help reduce the need for opioids by acting in certain areas of the brain called mu and ...

Sublocade (buprenorphine) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat moderate to severe opioid use disorder in people who received ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

Sublocade (buprenorphine) and Suboxone (buprenorphine/naloxone) are prescription drugs for opioid use disorder. Sublocade is injected by a healthcare professional and Suboxone is a film that dissolves ...

Sublocade is intended for use as part of a complete treatment program that includes counseling and psychosocial support. Sublocade is intended for use as part of a complete treatment program that ...

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition in the U.S. long-acting injectable (LAI) market and the discontinuation of ...

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...